您现在的位置：
晋城市公安局交警支队交通违法信息公告（11月20日-11月26日）
日 14:55:55&&&&来源：晋城在线
】&&【】&&【】
&&& 提示：“Ctrl+F”输入车牌号查询
日至日期间，下列机动车辆因违反道路交通安全法律法规，其交通违法行为被市区交通技术监控设备记录，现将其交通违法信息进行公告，请机动车辆驾驶人、机动车所有人及时到以下交通违法处理窗口接受处理。如对监控信息记录有异议，可到晋城市公安局交警支队指挥中心查询核实。&&&
晋城市辖区交通违法处理窗口：市通达汽车检测有限公司（南村检测线）、市长河机动车检测有限公司、市三安汽车检测有限公司、市交警一大队、市交警二大队、市交警三大队、市交警四大队、泽州县交警大队、高平市交警大队、阳城县交警大队、陵川县交警大队、沁水县交警大队。咨询电话：2126000。
&&& 共369条
豫A6BJ82& &晋EHU956& &晋EJX485& &晋EDF326&
&晋EZ9333晋EAX959& &晋E57822& &晋EJY902&
&晋EAE366& &晋EF3162晋EYX468& &晋EZX904&
&晋EV7558& &晋EPA842& &晋EQ5502晋EE8328&
&晋EN5198& &晋EXC008& &晋EFF288&
&晋E0508X晋E8C903& &晋EWL512& &晋EM0929&
&晋EF9948& &豫CVD077晋E15888& &晋EM2218&
&晋EXF618& &晋EZ6687& &晋E72606晋EYQ650&
&晋A839G3& &晋EP7659& &晋EJQ605&
&晋ECZ085晋EV1618& &苏E21DH1& &晋E73043&
&苏C995JK& &晋EZB386晋EA6551& &晋ER1433&
&晋EK2516& &晋A671W2& &晋EHE523晋E63668&
&晋EH2528& &晋EDC198& &晋ET0444&
&晋EFT808晋EAL527& &晋EW6419& &晋EZL717&
&晋EP5523& &晋E62276晋EZH956& &晋EE6930&
&晋AF238U& &晋EAH789& &晋E97680晋ERF516&
&晋EHE658& &晋E75810& &晋E81995&
&晋ELU616晋ER1204& &晋EXX501& &晋ES0710&
&晋E67676& &晋E36528晋EM0526& &晋ER7797&
&晋EY6818& &晋E88220& &晋EP5499晋EY0920&
&晋ELC720& &晋E89033& &豫AP78V0&
&晋E28413晋ELS083& &晋EJF756& &晋EKV528&
&晋EH8185& &晋E11755晋E90259& &晋E67593&
&晋EDY538& &晋EK2169& &晋ESJ328晋ERR122&
&苏AX7P30& &晋EG1291& &晋DLU229&
&晋EN5899晋EX3102& &晋ECY166& &晋EWZ870&
&晋E48078& &晋EWZ209晋EPQ912& &晋E00A50&
&鲁NGZ202& &晋EH5809& &晋EJ8588晋EJG588&
&晋ESY818& &晋EA8578& &晋ECL120&
&晋EEF386晋ED1509& &晋EHP018& &晋ER1182&
&晋E96735& &晋E62900晋E65011& &晋EG8831&
&晋LU3556& &晋EZS256& &晋E73885吉AL419E&
&晋EN8115& &晋ELS726& &鄂EHS460&
&晋ELZ194晋ESY057& &晋EHE366& &晋ES0397&
&晋E0001X& &晋E58251晋AG099A& &晋EX9552&
&晋FY2858& &晋E91067& &晋EQ0558晋E81786&
&晋EWM798& &晋ED1652& &晋E02138&
&晋ERC924晋EA7186& &晋ET0691& &晋ERZ968&
&晋ET0386& &晋EUW266晋AD7230& &晋ELP199&
&晋ES0152& &晋EC7646& &晋EMH691晋EA1176&
&晋EA3380& &晋E37777& &晋EFL825&
&晋EXJ677晋E86247& &晋EB9875& &晋EYY001&
&晋EKY123& &晋E68068晋EV6098& &晋EAE636&
&晋EL6330& &晋EC7765& &晋E75855晋E18018&
&晋EZ8859& &晋AZU650& &晋E84928&
&晋EE2965晋EFZ922& &晋ERR717& &晋EX3962&
&晋ECV626& &苏CB832R豫G2W970& &晋EJF217&
&晋EAB038& &晋EE3296& &晋ECZ004晋EG6969&
&晋EG9718& &晋EFN180& &晋EV0959&
&晋EA1446晋E9C150& &晋ES0417& &晋EF5302&
&晋EWZ528& &晋EY5533晋EMA660& &晋E81600&
&晋E80609& &晋E8B298& &晋EZF193晋ENN036&
&鲁HM3777& &晋EAL768& &晋EAA388&
&晋E29213晋EE5895& &晋E68002& &晋ET0441&
&晋ER8667& &晋EP4984晋EW0787& &晋ER7156&
&晋D4E478& &晋EZF193& &晋EX3231晋EV6662&
&晋EVH656& &晋EVW639& &豫EDK655&
&晋ET0232晋EWY515& &晋EX6818& &晋ET0355&
&晋EDY856& &晋EXL129晋EY7656& &晋EBW998&
&晋EY3349& &晋E50566& &晋EY5016晋EAQ599&
&黑F8369A& &晋EMH258& &晋EJ9886&
&晋E8C151豫EKV836& &晋E13A29& &晋EJL967&
&豫EMG826& &晋EZW223晋EJB938& &晋EMY955&
&晋E35329& &晋EFY181& &晋EV6587晋EV0922&
&晋ES8023& &晋EWY963& &晋E29975&
&晋EJ1986晋EK7659& &晋E88261& &晋EB5996&
&晋E97621& &晋EG2051晋ER5689& &晋EZE999&
&晋E92756& &晋A792J3& &晋ED2889晋EN5175&
&晋ER2416& &晋EF8095& &晋EWZ655&
&晋EKL960晋EL9666& &晋EW8787& &晋A0769T&
&晋E80657& &浙G213DB晋EW1054& &豫LUE828&
&闽DG286S& &晋E10969& &晋A98D71晋EMD698&
&晋E0A390& &晋EJ9829& &晋DW1217&
&晋EC1186晋DL3728& &晋EG2606& &晋EWG298&
&晋EQ1270& &晋EL0745晋EG0014& &晋EG1153&
&晋EG0014& &皖LPD988& &晋EJQ668晋EZ5631&
&晋E58329& &晋EYL439& &晋E82361&
&晋EE9345晋E23139& &晋EYG001& &苏CB832R&
&晋E29556& &晋E36936晋E72606& &豫EWM652&
&晋ESZ839& &晋ELN138& &晋EKX907晋EWP101&
&晋EWJ073& &晋EFY003& &晋E26532&
&晋ELF516晋EA8386& &晋EA0698& &晋ELE468&
&晋EW7971& &晋EHZ776晋EGQ798& &晋ERN595&
&晋E59333& &晋EV2836& &晋ELC719晋EM6818&
&晋ER5839& &晋ELY658& &晋E96075&
&晋EZ0260晋E85988& &晋E68458& &晋E59918&
&晋ELQ688& &晋EKL110晋EU3698& &豫AV71E5&
&晋EV6987& &晋E52881& &晋EE5805晋ESM788&
&豫NYJ202& &晋ESH588& &晋ELF953&
&晋EWX561晋ECC361& &晋EHM629& &晋EVW009&
&晋EF8565& &晋ES8650晋EW2044& &晋EE6366&
&晋EK5600& &晋EUF070& &晋E26078晋E62929&
&晋EA8896& &晋EHB420& &晋ELX719&
&豫DW3321晋ELN151& &晋EV8977& &晋EV8966&
&晋EM5112& &晋ER8619晋EA3975& &晋EZL532&
&晋EH6684& &晋ELF419& &晋EV6345晋E24143&
&晋EBC689& &晋EA9996& &晋ETT378&
&晋ELQ506晋E00269& &晋EH3877& &豫CTV135&
责编：莫潞伟
【】&&&【】&&&【】&&&【】&&&【】
&&相关链接
& 09:49:13
& 16:43:56
& 16:28:42
& 16:24:00
& 10:33:38
　　您还要浏览：
晋城在线版权与免责声明：
① 凡本网注明&稿件来源：晋城在线& 的所有文字、图片和音视频稿件，版权均属晋城市信息中心所有，任何媒体、网站或个人未经本网协议授权不得转载、链接、转贴或以其他方式复制发表。已经本网协议授权的媒体、网站，在下载使用时必须注明&稿件来源：晋城在线&，违者本网将依法追究责任。
② 本网未注明& 稿件来源：晋城在线&的文/图等稿件均为转载稿，本网转载出于传递更多信息之目的，并不意味着赞同其观点或证实其内容的真实性。如其他媒体、网站或个人从本网下载使用，必须保留本网注明的&稿件来源&，并自负版权等法律责任。如擅自篡改为&稿件来源：晋城在线&，本网将依法追究责任。如对稿件内容有疑议，请及时与我们联系。
③ 如本网转载稿涉及版权等问题，请作者在两周内速来电或来函与我们联系，我们将及时按作者意愿予以更正。免费电话：400-668-6834 | 技术支持：400-168-6834 | 邮箱：
BMS-754807
BMS-754807
Catalog No.S1124
Molecular Weight(MW): 461.49
BMS-754807是一种有效的IGF-1R/InsR可逆性抑制剂，在无细胞试验中IC50为1.8 nM/1.7 nM，对Met，Aurora A/B，TrkA/B和Ron作用稍弱，对Flt3， Lck，MK2，PKA，PKC等几乎没有抑制活性。Phase 2。
今日订购，明日送达，全国免运费！
全国免费电话：400-668-6834&&&|&&&Email：
客户使用该产品发表的文献5篇：
客户使用该产品的1个实验数据：
Clin Cancer Res
19(11), 2984-94.
BMS-754807 purchased from Selleck.
产品安全说明书
IGF-1R抑制剂选择性比较
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值
2. 更多细节，例如半抑制浓度（IC50）以及任何抑制剂的相关工作浓度，请点击您感兴趣抑制剂的链接。
3. "+"代表抑制作用的强度。"+"越多，抑制作用越强。
4. 橙色的"√"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。
BMS-754807是一种有效的IGF-1R/InsR可逆性抑制剂，在无细胞试验中IC50为1.8 nM/1.7 nM，对Met，Aurora A/B，TrkA/B和Ron作用稍弱，对Flt3， Lck，MK2，PKA，PKC等几乎没有抑制活性。Phase 2。
胰岛素样生长因子-1R/IR家族激酶的多重抑制剂
Insulin Receptor (Cell-free assay)
IGF-1R (Cell-free assay)
TrkB (Cell-free assay)
Met (Cell-free assay)
TrkA (Cell-free assay)
BMS-754807 有效抑制人类多种不同组织来源的肿瘤细胞系的生长，包括间充质（尤文氏肉瘤，横纹肌肉瘤，神经母细胞瘤，和脂肪肉瘤），上皮（乳腺，肺，胰腺，结肠，和胃），和造血（多发性骨髓瘤和白血病）组织，IC50值从5 nM 到 365 nM。BMS-754807 抑制 IGF-1R-Sal 细胞和 RH41细胞增殖，IC50分别为7 nM 和5 nM。BMS-754807作用于IGF-1R-Sal, Rh41 和 Geo细胞，抑制IGF-1R磷酸化，IC50分别为13 nM, 6 nM 和 21 nM。BMS-754807作用于 IGF-1R-Sal, Rh41 和Geo细胞，抑制Akt磷酸化，IC50 分别为22 nM, 13 nM 和 16 nM。BMS-754807诱导Rh41细胞凋亡。 BMS-754807作用于IGF-Sal 细胞系，抑制IGF-1R (IC50 = 13nM) 和下游靶点Akt (IC50 = 22nM) 和MAPK(IC50 = 13nM) 的磷酸化。 在儿科临床前期试验计划（PPTP）中，BMS-754807作用于23种细胞系，平均EC50值为0.62 uM。
Cell Lines
Assay Type
Concentration
Incubation Time
Formulation
Activity Description
MnXST4lv[XOnIHHzd4F6
NF3yXWFqdmirYnn0d{B1cGVicHjvd5Bpd3K7bHH0bY9vKG:oIFnHSk0yWiBqSVO1NEA:KDF|bl2pJIFv\CC2aHWg[I94dnO2cnXhcUB1[XKpZYTzJGFsfCBqSVO1NEA:KDJ{bl2pJIFv\CCPQWDLJEhKSzVyIE2gNVNvVSl?
NI\UdGUyQTd5OECyOC=&
MWjHdo94fGhiaX7obYJqfG:{eTDhd5NigQ&?
MXXJR|UxRTdibl2=
Ml7aNVk4PzhyMkS=
CCRF-CEM (ALL)
MnLqS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?
M1XHPZ42KM7:TR?=
NFX6W2RFVVOR
MnzCTWM2OD1zLkKzPUDPxE1?
NFS5c2gyQTl7NkK3Ni=&
NI\tdYFIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=
NIDle5J,PSEQvF2=
Ml7hSG1UVw&?
MnjqTWM2OD1yLkm2OUDPxE1?
NFraUGkyQTl7NkK3Ni=&
MWXHdo94fGhiaX7obYJqfG:{eTDhd5NigQ&?
M3zWNp42KM7:TR?=
NHeySnRFVVOR
MljrTWM2OD1yLkO5NUDPxE1?
Mom3NVk6QTZ{N{K=
NWjq[YFWT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm=
MWf+OUDPxE1?
M{myfWROW09?
MXXJR|UxRTFwNE[1JO69VQ&?
NUDr[JIyOTl7OU[yO|I&
MXvHdo94fGhiaX7obYJqfG:{eTDhd5NigQ&?
MVX+OUDPxE1?
NH7NdHJFVVOR
NV:3TFlSUUN3ME2xMlY3PSEQvF2=
NHHnVG0yQTl7NkK3Ni=&
K-562 (CML)
MX\Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ&?
MnXlglUh|ryP
NHH2ZoJKSzVyPUKuN|AzKM7:TR?=
MXqxPVk6PjJ5Mh?=
B6-P210 (Murine ALL)
NUDGfog1T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm=
MVz+OUDPxE1?
MmHuSG1UVw&?
MWPJR|UxRTFwMkmzJO69VQ&?
MYCxPVk6PjJ5Mh?=
LN CAP-FGC
MXXHdo94fGhiaX7obYJqfG:{eTDhd5NigQ&?
MUj+OUDPxE1?
NWHkUVdETE2VTx?=
NVrv[FR5UUN3ME2xMlQ{PCEQvF2=
M2S2SVE6QTl4Mkey
NY\tbFB[T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm=
NUnaRXVshjVizszN
Mni2SG1UVw&?
Mn\iTWM2OD1yLkCxPUDPxE1?
MYKxPVk6PjJ5Mh?=
MV411 (B Myelomonocytic)
MX3Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ&?
Mkf6glUh|ryP
MnW1SG1UVw&?
M2[3UGlEPTB;MD6zN{DPxE1?
NHvKdGUyQTl7NkK3Ni=&
MDA-PCa-2b
MWHHdo94fGhiaX7obYJqfG:{eTDhd5NigQ&?
M3G2Zp42KM7:TR?=
MU\JR|UxRTBwMEm4JO69VQ&?
NFy2UYUyQTl7NkK3Ni=&
MlPmS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?
M2K5Np42KM7:TR?=
Mn\JSG1UVw&?
NXTEcFd6UUN3ME2wMlA{QCEQvF2=
Mo\MNVk6QTZ{N{K=
RS411 (B cell precursor-ALL)
Mo\pS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?
NVj4[pYyhjVizszN
MVvJR|UxRTBwMUCyJO69VQ&?
NGrQU2cyQTl7NkK3Ni=&
MXzHdo94fGhiaX7obYJqfG:{eTDhd5NigQ&?
M4myTp42KM7:TR?=
NX;6SoNjTE2VTx?=
M3zUdGlEPTB;MD6xO|Uh|ryP
M3\MXFE6QTl4Mkey
NFHEO4tIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=
NHHvWIx,PSEQvF2=
M3riXmROW09?
NXr0W5JqUUN3ME2wMlA{PCEQvF2=
MVyxPVk6PjJ5Mh?=
P388 (Murine)
MYfHdo94fGhiaX7obYJqfG:{eTDhd5NigQ&?
NVn0TYE2hjVizszN
M1HZemROW09?
MXLJR|UxRTRwMkeg{txO
M{nYN|E6QTl4Mkey
MmS4S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?
NWHIU2p2hjVizszN
NH75PXlFVVOR
M1[yT2lEPTB;MD6xNlIh|ryP
Ml6wNVk6QTZ{N{K=
Ml\LS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?
NWfK[mI6hjVizszN
M3mweWROW09?
NF\QRnpKSzVyPUCuNFEzKM7:TR?=
MXuxPVk6PjJ5Mh?=
B6-T315I (Murine B-ALL)
NYDqdYh4T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm=
NWTuZ3M4hjVizszN
NEHDcoJFVVOR
NWrRWYRRUUN3ME2yMlg{KM7:TR?=
Ml3yNVk6QTZ{N{K=
MV;Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ&?
NV\tfYNYhjVizszN
NWD5Z|lbTE2VTx?=
M{PxRmlEPTB;Mj6xOFYh|ryP
NHjGXGQyQTl7NkK3Ni=&
NGWyc5RIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=
MU\+OUDPxE1?
Mk\OSG1UVw&?
M4j3PGlEPTB;MD6wNFgh|ryP
MWexPVk6PjJ5Mh?=
HL60 (acute myelocytic)
NWXERWNqT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm=
MVz+OUDPxE1?
NGPUT4xFVVOR
NXHOflBUUUN3ME2wMlEzKM7:TR?=
MYqxPVk6PjJ5Mh?=
M{LPWGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7
NUjKdpJbhjVizszN
M{jLPWROW09?
M2jhTWlEPTB;ND6yO|kh|ryP
MUGxPVk6PjJ5Mh?=
NYDMempjT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm=
NFO0cnR,PSEQvF2=
NX2xZphFTE2VTx?=
MUTJR|UxRTBwMEG0JO69VQ&?
Mk\0NVk6QTZ{N{K=
HPN-ALL (T-cell)
M2TqTGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7
M{DtXp42KM7:TR?=
MnGySG1UVw&?
NVzLb2dSUUN3ME2wMlUzKM7:TR?=
M3zJXVE6QTl4Mkey
M4PVNmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7
MY\+OUDPxE1?
MknSSG1UVw&?
NI\BfVdKSzVyPUGuOVY1KM7:TR?=
M1vQOFE6QTl4Mkey
NW\Je3J1T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm=
NWntOmtZhjVizszN
MWHJR|UxRTBwMEK3JO69VQ&?
MkPPNVk6QTZ{N{K=
Kasumi-1 (acute myeloid)
NFznVo1Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?=
MlKxglUh|ryP
NF;6N5dFVVOR
M2rFeGlEPTB;MD6xOkDPxE1?
MUOxPVk6PjJ5Mh?=
Mm\MS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?
NWjlfFFHhjVizszN
M1G3[mlEPTB;NT6xJO69VQ&?
NFLLeGcyQTl7NkK3Ni=&
NF\FToRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=
MWj+OUDPxE1?
NHixbpBFVVOR
MV\JR|UxRTBwMEG1JO69VQ&?
NXLKN5RxOTl7OU[yO|I&
L1210 (Murine lymphocytic)
NIjzU4lIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=
MmrxglUh|ryP
NVroO3RNTE2VTx?=
NX\VRXd3UUN3ME2yMlM6KM7:TR?=
MnHpNVk6QTZ{N{K=
NFmxdItIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=
M33PUp42KM7:TR?=
NGewO45FVVOR
MWrJR|UxRTJwM{C2JO69VQ&?
NXvveFlPOTl7OU[yO|I&
MmTOS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?
MX7+OUDPxE1?
NFzkXWtKSzVyPUCuNlU{KM7:TR?=
M2qyOFE6QTl4Mkey
ML2 (Myelomonocytic)
M1\nNGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7
NVP6RlNZhjVizszN
NFXxSVdFVVOR
MmrWTWM2OD1yLkC5JO69VQ&?
MnvaNVk6QTZ{N{K=
NX;zUFd5T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm=
Mln4glUh|ryP
NUDrZW9nTE2VTx?=
MkG4TWM2OD13IN88US=&
NIT5XogyQTl7NkK3Ni=&
NYqzeo44T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm=
M1[2VZ42KM7:TR?=
NEPhTpdFVVOR
MX7JR|UxRTFwNEOyJO69VQ&?
NVTzW41MOTl7OU[yO|I&
MOLM-13 (acute myeloid)
NIS3ZWxIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=
NYDXRZdjhjVizszN
NETCZ5ZFVVOR
M4L2fWlEPTB;MD60NkDPxE1?
MlPBNVk6QTZ{N{K=
NInCVoZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=
NFfKTVJ,PSEQvF2=
M2nzXmROW09?
Mn6wTWM2OD1zIN88US=&
MUGxPVk6PjJ5Mh?=
NG\tdllIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=
MVj+OUDPxE1?
M4rBemROW09?
NUSxfo1vUUN3ME2wMlAxPSEQvF2=
MoLZNVk6QTZ{N{K=
Mutz 2 (acute myeloid)
Ml;6S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?
NUjzRZlChjVizszN
M3f0ZWROW09?
MlS4TWM2OD1zLkG1JO69VQ&?
M1G3Z|E6QTl4Mkey
MmDiS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?
Mn73glUh|ryP
Mo\xSG1UVw&?
NWXadJVYUUN3ME2wMlA2KM7:TR?=
M3\sUVE6QTl4Mkey
MnXuS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?
MYH+OUDPxE1?
NH3qfIRFVVOR
MVrJR|UxRTBwME[4JO69VQ&?
M1HUSVE6QTl4Mkey
OCI-AML 2 (acute myeloid)
NV;uXVVOT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm=
NUjvS2luhjVizszN
M2PR[2lEPTB;Mz6zN{DPxE1?
M2PqcFE6QTl4Mkey
NUHWcGd3T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm=
M4mzZ542KM7:TR?=
Mn\qTWM2OD1zLk[0O{DPxE1?
NGH1emEyQTl7NkK3Ni=&
NWnFSJNoT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm=
MYH+OUDPxE1?
NF\MdXRKSzVyPUCuOFA5KM7:TR?=
Mle0NVk6QTZ{N{K=
TALL-1 (T-cell)
NGTRVZRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=
MXj+OUDPxE1?
MoCwSG1UVw&?
MoPmTWM2OD1zLkK4JO69VQ&?
MW[xPVk6PjJ5Mh?=
NVnBSVFNT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm=
NXznN|VrhjVizszN
NVvxWFM{TE2VTx?=
Mn3KTWM2OD1{Lk[3JO69VQ&?
MUexPVk6PjJ5Mh?=
NHfUUHRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=
MXH+OUDPxE1?
NHLWe5lKSzVyPUCuNVMzKM7:TR?=
NFLYS2EyQTl7NkK3Ni=&
M1jJcWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7
NHLPZWJ,PSEQvF2=
NUfsRVBPTE2VTx?=
MmrPTWM2OD14LkW4JO69VQ&?
Mmi3NVk6QTZ{N{K=
MUTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ&?
NY\0SJpIhjVizszN
M4ToU2ROW09?
MVPJR|UxRTBwOUG1JO69VQ&?
MYqxPVk6PjJ5Mh?=
MnzpS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?
MnXNglUh|ryP
M3XSS2ROW09?
M3Pqd2lEPTB;MT65O|kh|ryP
NU\GT41DOTl7OU[yO|I&
NXrXTnNyT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm=
MXL+OUDPxE1?
MoXySG1UVw&?
MmXETWM2OD1yLkK5PEDPxE1?
NFHEeW8yQTl7NkK3Ni=&
NVX0SpQ{T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm=
M4TNeJ42KM7:TR?=
M1q3b2lEPTB;NT6yOUDPxE1?
M3v1VVE6QTl4Mkey
M4H3Rmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7
MnzaglUh|ryP
M1LLemROW09?
NFnEXZBKSzVyPUCuOFk4KM7:TR?=
MVOxPVk6PjJ5Mh?=
NEH4cZJIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=
M1jPfp42KM7:TR?=
NVfZW25kTE2VTx?=
M3;4TWlEPTB-MT6wNEDPxE1?
NXPEcYRJOTl7OU[yO|I&
M1z4dWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7
NY[y[3EzhjVizszN
MVfJR|UxRTJwMEW2JO69VQ&?
MUOxPVk6PjJ5Mh?=
MWHHdo94fGhiaX7obYJqfG:{eTDhd5NigQ&?
MlHDglUh|ryP
MlLHSG1UVw&?
MYTJR|UxRTBwMESg{txO
NXnEOHNwOTl7OU[yO|I&
MXLHdo94fGhiaX7obYJqfG:{eTDhd5NigQ&?
NHXYV5B,PSEQvF2=
NF36fVdFVVOR
MWTJR|UxRTFwMUmg{txO
NHX1Nm0yQTl7NkK3Ni=&
NUnvVnF3T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm=
NWPtVpJKhjVizszN
M17SfWlEPTB;Mj6wNFEh|ryP
MUCxPVk6PjJ5Mh?=
MljRS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?
MW\+OUDPxE1?
NYnnO3ptUUN3ME2wMlI3OSEQvF2=
NIrDZ5oyQTl7NkK3Ni=&
Daudi (Burkitt's)
MYPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ&?
NXG2S|VPhjVizszN
NXvZR3o1TE2VTx?=
NHHsS49KSzVyPUKuOlM4KM7:TR?=
M4fnOFE6QTl4Mkey
NVO2WoRsT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm=
MV\+OUDPxE1?
MnjSSG1UVw&?
MWLJR|UxRTBwM{e5JO69VQ&?
MknXNVk6QTZ{N{K=
NH7HU4pIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=
NVjnNlJzhjVizszN
MnzzSG1UVw&?
NW\2WWZ2UUN3ME2wMlE{QSEQvF2=
MorpNVk6QTZ{N{K=
MEC-1 (Chronic B cell)
NGXSNYhIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=
NWjEVZBshjVizszN
MlWwSG1UVw&?
MXjJR|UxRTJwNkO3JO69VQ&?
NFTPWYgyQTl7NkK3Ni=&
Mmi4S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?
MYj+OUDPxE1?
NXWxWI14TE2VTx?=
NYTCOIg5UUN3ME2xMlc4PCEQvF2=
NIn1TpIyQTl7NkK3Ni=&
NIjvN45Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?=
MWn+OUDPxE1?
Mn2xSG1UVw&?
M1;mT2lEPTB;MD6xNFYh|ryP
M3vITFE6QTl4Mkey
U937 (Histioocytic)
M{nxXmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7
MYH+OUDPxE1?
MlHBSG1UVw&?
NVvPW2JkUUN3ME61MlAxKM7:TR?=
NX3ZOnV3OTl7OU[yO|I&
MkPyS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?
NGX0Z3V,PSEQvF2=
NXjaUHVmTE2VTx?=
NGLyVW1KSzVyPUGuPVI1KM7:TR?=
MlO3NVk6QTZ{N{K=
NXjKeYQyT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm=
NYPReGtMhjVizszN
M2fCeGROW09?
NYTacXFxUUN3ME61MlAxKM7:TR?=
NXz4ToZEOTl7OU[yO|I&
MV;Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ&?
NWjEZY1JhjVizszN
Mn;UTWM2OD1zLkCyJO69VQ&?
MnW3NVk6QTZ{N{K=
OCI-LY10 (B-cell)
MnKxS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?
NV3F[FdphjVizszN
NFfkcpZFVVOR
M4XEUmlEPTB;MD60OUDPxE1?
NGPpOVYyQTl7NkK3Ni=&
MYrHdo94fGhiaX7obYJqfG:{eTDhd5NigQ&?
NIKwU|B,PSEQvF2=
MkPqSG1UVw&?
NEnFSJVKSzVyPkWuNFAh|ryP
MmLTNVk6QTZ{N{K=
M2LiNWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7
M3nWUJ42KM7:TR?=
NH7qbItKSzVyPUCuOFY6KM7:TR?=
NXTZSIx1OTl7OU[yO|I&
OCI-LY19 (B-cell)
NIT1e|RIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=
NX:zTmlMhjVizszN
M{\NbmROW09?
M3\NWmlEPTB;MD60JO69VQ&?
M{DLd|E6QTl4Mkey
M2Xo[2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7
NF:zeWd,PSEQvF2=
NW\KSoJDTE2VTx?=
MX\JR|UxRjVwMECg{txO
NXfXXXQyOTl7OU[yO|I&
NX7qVpdST3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm=
NYDpbHgzhjVizszN
MnjUSG1UVw&?
MmPnTWM2OD1zLkOwNUDPxE1?
MWWxPVk6PjJ5Mh?=
M4m1fmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7
NHHxfXZ,PSEQvF2=
NITiWmVFVVOR
NXLBXHUxUUN3ME2xMlI6OyEQvF2=
NXfjN2NbOTl7OU[yO|I&
MkTuS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?
M{LtO542KM7:TR?=
Mn3NSG1UVw&?
M2\kemlEPTB;MD62OFQh|ryP
NVHYOGFXOTl7OU[yO|I&
MYPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ&?
M{\WN542KM7:TR?=
M4DuV2ROW09?
MXrJR|UxRTFwOEi4JO69VQ&?
NHPRfoYyQTl7NkK3Ni=&
NViyeFZsT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm=
NXqwW2hKhjVizszN
MnjvSG1UVw&?
NYX4c4V{UUN3ME2xMlY3QSEQvF2=
M4\BWVE6QTl4Mkey
MXPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ&?
NWfCVno6hjVizszN
NFzE[ZBFVVOR
MVTJR|UxRTBwMkOxJO69VQ&?
MlXLNVk6QTZ{N{K=
NHPjfpNIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=
MoXBglUh|ryP
NEK4NYtFVVOR
MXXJR|UxRTFwMUW0JO69VQ&?
M1ftSlE6QTl4Mkey
NFfsdHNIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=
NGriTlR,PSEQvF2=
MnXzSG1UVw&?
NH7ZPG1KSzVyPUCuNFE1KM7:TR?=
NF3jO2EyQTl7NkK3Ni=&
NVTa[JVMT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm=
NFHsWGR,PSEQvF2=
NVTm[4tIUUN3ME2yMlI2PSEQvF2=
NYHJc25xOTl7OU[yO|I&
Mnr6S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?
MnTXglUh|ryP
Ml3ISG1UVw&?
MWnJR|UxRjVwMECg{txO
M3LZN|E6QTl4Mkey
NFXSW2RIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=
NHH5Upp,PSEQvF2=
Mm\FSG1UVw&?
NWTnNIVlUUN3ME2yMlQ{OyEQvF2=
Mmi4NVk6QTZ{N{K=
MXXHdo94fGhiaX7obYJqfG:{eTDhd5NigQ&?
MXr+OUDPxE1?
M3XHT2ROW09?
NXvrWmk1UUN3ME2yMlY4OiEQvF2=
NVrPdoJGOTl7OU[yO|I&
NUTHfowzT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm=
MUH+OUDPxE1?
M3r2TWROW09?
MX7JR|UxRjVwMECg{txO
MYixPVk6PjJ5Mh?=
MDA-MB-468
NHW1O2ZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=
MoTjglUh|ryP
NXHYSGo5TE2VTx?=
MmS3TWM2OD1yLkWwOEDPxE1?
M32xVVE6QTl4Mkey
NVGwTFFXT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm=
NUX6bZp3hjVizszN
NFq4XpNFVVOR
Mn\OTWM2OD1yLkiyOkDPxE1?
NIfJNo4yQTl7NkK3Ni=&
MlHrS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?
MXz+OUDPxE1?
Mm\oSG1UVw&?
MUHJR|UxRjVwMECg{txO
M{XHdlE6QTl4Mkey
MDA-MB-231
M1jOU2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7
MX7+OUDPxE1?
M4rpWWROW09?
NYPPXm1JUUN3ME2xMlY1QCEQvF2=
M3PKWVE6QTl4Mkey
MULHdo94fGhiaX7obYJqfG:{eTDhd5NigQ&?
M4jEfp42KM7:TR?=
MkeySG1UVw&?
NGnme2lKSzVyPkWuNFAh|ryP
NHu2eYYyQTl7NkK3Ni=&
MkfWS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?
NIrje4d,PSEQvF2=
M2nJZmROW09?
NGn6bYhKSzVyPUGuNVk{KM7:TR?=
M32wS|E6QTl4Mkey
MDA-MB-231T
NVLRTJVOT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm=
NV3CZY1bhjVizszN
M1TxN2lEPTB-NT6wNEDPxE1?
MYexPVk6PjJ5Mh?=
MmizS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?
MWn+OUDPxE1?
M1\OXGlEPTB;MD61N|Eh|ryP
MWWxPVk6PjJ5Mh?=
H526 0.044
M2HtcWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7
NWSzVmM1hjVizszN
M3T5eGROW09?
NGrw[GtKSzVyPUCuNFQ1KM7:TR?=
NYrh[XZVOTl7OU[yO|I&
NEXlNnNIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=
NGPBZll,PSEQvF2=
Ml7ESG1UVw&?
NHfrPFdKSzVyPUKuOFMyKM7:TR?=
M2\hclE6QTl4Mkey
MXHHdo94fGhiaX7obYJqfG:{eTDhd5NigQ&?
M{jhNZ42KM7:TR?=
MoG0SG1UVw&?
NX\xS5JlUUN3ME2wMlg2OiEQvF2=
NF7BPGEyQTl7NkK3Ni=&
MV7Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ&?
Mn7rglUh|ryP
M4XrO2ROW09?
MkGxTWM2OD1zLkC1OUDPxE1?
MXKxPVk6PjJ5Mh?=
MUDHdo94fGhiaX7obYJqfG:{eTDhd5NigQ&?
MYn+OUDPxE1?
NVH1WmVDUUN3ME2xMlY1PSEQvF2=
MmCwNVk6QTZ{N{K=
HCT116/VM46
MVzHdo94fGhiaX7obYJqfG:{eTDhd5NigQ&?
M4rwWZ42KM7:TR?=
M2rOeGlEPTB;MT63NFIh|ryP
NVrYfIhnOTl7OU[yO|I&
M1TtNWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7
NUXyV214hjVizszN
MV;JR|UxRTBwN{m1JO69VQ&?
M1nnTlE6QTl4Mkey
M13xOWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7
M1HRXZ42KM7:TR?=
MkTuTWM2OD1yLkCxOkDPxE1?
MWmxPVk6PjJ5Mh?=
NXzUN2NDT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm=
NVTQRXlohjVizszN
NFPKUpRFVVOR
MmLHTWM2OD1yLkO1OkDPxE1?
NHHEc|kyQTl7NkK3Ni=&
H441 0.646
NUn1Xm03T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm=
MWT+OUDPxE1?
NGXYdZBFVVOR
NV[5dlVQUUN3ME2wMlY1PiEQvF2=
MoHUNVk6QTZ{N{K=
MCF-7-807R
MYPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ&?
MWD+OUDPxE1?
M4rkVGROW09?
NETYXY9KSzVyPUCuOFkh|ryP
NVe2b4FGOTl7OU[yO|I&
M4DlNWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7
MlnTglUh|ryP
M1HSbWROW09?
NV6yZ2hQUUN3ME2wMlExPCEQvF2=
NHrJPGoyQTl7NkK3Ni=&
NUHnOZJCT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm=
MXz+OUDPxE1?
NILLNJpFVVOR
M{PVO2lEPTB;MD63PFgh|ryP
MoO4NVk6QTZ{N{K=
NVTnboV[T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm=
MVT+OUDPxE1?
NYPo[GJpTE2VTx?=
Mni2TWM2OD1{LkSwN{DPxE1?
NEnIXFEyQTl7NkK3Ni=&
MX3Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ&?
MYL+OUDPxE1?
NX64R3hzUUN3ME2yMlExOyEQvF2=
M4XKb|E6QTl4Mkey
M2KzTWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7
NV;0dmV{hjVizszN
M2jPU2ROW09?
NF6wSGxKSzVyPUCuOlc2KM7:TR?=
NHXoc|QyQTl7NkK3Ni=&
MlnSS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?
NYftdVBOhjVizszN
MljaSG1UVw&?
MlXtTWM2OD1{LkO2OUDPxE1?
MlH3NVk6QTZ{N{K=
NXPJWod[T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm=
MXj+OUDPxE1?
NUXqcG1nTE2VTx?=
M{HrZ2lEPTB-NT6wNEDPxE1?
MkTENVk6QTZ{N{K=
NUjZPW5tT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm=
NYrkN5VbhjVizszN
MnLzSG1UVw&?
Ml3ETWM2OD1yLkS0NkDPxE1?
NV3xcGkxOTl7OU[yO|I&
M3vOdWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7
NV61S2w4hjVizszN
MkXvTWM2OD12Lkm3JO69VQ&?
MYWxPVk6PjJ5Mh?=
NEXQc|lIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=
NV\T[lVlhjVizszN
M{XIemROW09?
M1nrWGlEPTB;MD6yNkDPxE1?
M1\teFE6QTl4Mkey
MV;Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ&?
MXf+OUDPxE1?
M{mwPGROW09?
M3P6UGlEPTB;MD61NlMh|ryP
MlOzNVk6QTZ{N{K=
NFHKOWxIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=
MkL5glUh|ryP
NFO2ZoNFVVOR
MlHXTWM2OD1|LkW2NkDPxE1?
NFj1PIgyQTl7NkK3Ni=&
Colo320HSR
MVzHdo94fGhiaX7obYJqfG:{eTDhd5NigQ&?
NWLB[5lHhjVizszN
NWPzW3F[TE2VTx?=
MXvJR|UxRTBwMEGxJO69VQ&?
M2DSZlE6QTl4Mkey
MV3Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ&?
MojwglUh|ryP
NWmxPJZwTE2VTx?=
Mmf0TWM2OD5zLkCwJO69VQ&?
NGX4N3oyQTl7NkK3Ni=&
NWTiUY01T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm=
Ml73glUh|ryP
NEDJS2JFVVOR
MoLaTWM2OD1{LkWxO{DPxE1?
NGDxRZgyQTl7NkK3Ni=&
NEPwN|JIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=
NWf2b|EzhjVizszN
NFf2d3dFVVOR
NF25PVNKSzVyPUCuNFc3KM7:TR?=
M1zmblE6QTl4Mkey
H661 0.573
NXqx[|FFT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm=
NIDXZ4t,PSEQvF2=
MlnESG1UVw&?
NXrtZW1OUUN3ME2wMlU4OyEQvF2=
NHnSSlYyQTl7NkK3Ni=&
MlSzS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?
NUTwPGZ[hjVizszN
M3vzb2ROW09?
NHzzdpRKSzVyPkWuNFAh|ryP
Mn3tNVk6QTZ{N{K=
M2P3TWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7
MnvCglUh|ryP
M1P6bWlEPTB;MD61N|Uh|ryP
NEWze4oyQTl7NkK3Ni=&
NYj6SpRrT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm=
NHvpOlN,PSEQvF2=
M4T3R2ROW09?
MYjJR|UxRTBwN{OzJO69VQ&?
M2jCNFE6QTl4Mkey
NVrhUG1rT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm=
MUL+OUDPxE1?
NUXRUXJSUUN3ME2xMlU2KM7:TR?=
NVW4bY94OTl7OU[yO|I&
M3HS[2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7
M{\wNJ42KM7:TR?=
NFTLO4RFVVOR
M1HibGlEPTB;MD6wOlch|ryP
MVixPVk6PjJ5Mh?=
NFPucXpIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=
MoP3glUh|ryP
M3exV2ROW09?
NYmz[Y5UUUN3ME20MlQ1QCEQvF2=
NIHle4EyQTl7NkK3Ni=&
MDA-MB-157
M4\afGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7
M1j5Sp42KM7:TR?=
M3;IfGROW09?
NXH4eoNsUUN3ME2wMlA{PiEQvF2=
Ml7GNVk6QTZ{N{K=
NELkVI9Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?=
NFnpZmN,PSEQvF2=
NXzRZYdUTE2VTx?=
MlvxTWM2OD1zLkC1JO69VQ&?
NIfFSI0yQTl7NkK3Ni=&
MDA-MB-415
MU\Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ&?
M3HzXJ42KM7:TR?=
NHHBeJZFVVOR
NIDHfGJKSzVyPkWuNFAh|ryP
MUmxPVk6PjJ5Mh?=
MkLRS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?
M1XWR542KM7:TR?=
MkTrSG1UVw&?
MWXJR|UxRTBwOUC5JO69VQ&?
Mmj1NVk6QTZ{N{K=
M3zzSGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7
NHLBXZd,PSEQvF2=
M2ntbGROW09?
NX3UVG04UUN3ME20MlQ4PSEQvF2=
MWGxPVk6PjJ5Mh?=
MDA-MB-435S
M3PYb2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7
M1foUp42KM7:TR?=
NVfpVnR5UUN3ME2xMlg3QSEQvF2=
MWixPVk6PjJ5Mh?=
NYDFT4FYT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm=
MWL+OUDPxE1?
M{nmbWROW09?
M1TUfGlEPTB-MT6wNEDPxE1?
MoPZNVk6QTZ{N{K=
NXXmZolyT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm=
NIXiZ3N,PSEQvF2=
MkDNSG1UVw&?
NUnE[oI6UUN3ME2wMlE1PiEQvF2=
MVyxPVk6PjJ5Mh?=
MDA-MB-436
NUHwRWczT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm=
NH\SZZV,PSEQvF2=
NFS3V4pFVVOR
MU\JR|UxRTVwNUCyJO69VQ&?
NU\3Tnh4OTl7OU[yO|I&
M3u3WGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7
M{fle542KM7:TR?=
MmfhSG1UVw&?
MkX2TWM2OD1yLkC1OEDPxE1?
NEOxRm0yQTl7NkK3Ni=&
Mo\pS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?
NWT0VYdThjVizszN
NHLicZpFVVOR
MlrpTWM2OD1yLkCyOUDPxE1?
NVP2XVZ{OTl7OU[yO|I&
MDA-MB-453
MnTDS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?
MYf+OUDPxE1?
M2\ZU2ROW09?
NXG4dWZCUUN3ME2xMlg3QSEQvF2=
MVGxPVk6PjJ5Mh?=
MlPMS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?
NXm2PYhThjVizszN
MmTaSG1UVw&?
NHHVUFBKSzVyPUCuNFU6KM7:TR?=
NXf3NVAyOTl7OU[yO|I&
NI\KWXJIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=
M3LGOp42KM7:TR?=
MXvJR|UxRTJwMUmg{txO
NXHpUWVVOTl7OU[yO|I&
NXO1eIxnT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm=
NUDMSYRzhjVizszN
Mmi2SG1UVw&?
M2XVdmlEPTB;MT6yPFch|ryP
MkK2NVk6QTZ{N{K=
MoPNS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?
M363b542KM7:TR?=
MmfISG1UVw&?
M3nEc2lEPTB;MD62PVYh|ryP
M2HLXlE6QTl4Mkey
NVLFVHpVT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm=
M2S1OJ42KM7:TR?=
NXHDXWFXTE2VTx?=
NH\yNHRKSzVyPUGuNlch|ryP
NWGxTWl3OTl7OU[yO|I&
MmHCS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?
NHnOZ2h,PSEQvF2=
MmS0SG1UVw&?
NXX3XFlOUUN3ME2yMlA5PCEQvF2=
MVWxPVk6PjJ5Mh?=
NXjqUG4{T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm=
M1PEcZ42KM7:TR?=
MnvKTWM2OD1yLkGzOUDPxE1?
NWnzfpRVOTl7OU[yO|I&
Detroit.562
MWXHdo94fGhiaX7obYJqfG:{eTDhd5NigQ&?
NVjOZVlQhjVizszN
MoTwSG1UVw&?
MnzoTWM2OD1zLkG0JO69VQ&?
NXnQ[JV6OTl7OU[yO|I&
NHvPTmlIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=
M4fuPJ42KM7:TR?=
NUf6NIZYTE2VTx?=
M4G1TGlEPTB-NT6wNEDPxE1?
NEf5SocyQTl7NkK3Ni=&
MoXQS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?
NXjZXpJyhjVizszN
Mkj3SG1UVw&?
MnvOTWM2OD1yLkKzNkDPxE1?
NWDOeHJ1OTl7OU[yO|I&
M4j6WGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7
M1XlTZ42KM7:TR?=
NV:5WYRMUUN3ME2yJO69VQ&?
NWDtRnlpOTl7OU[yO|I&
M1\ESmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7
Mlr6glUh|ryP
M3XwdWROW09?
MXvJR|UxRTFwMkWyJO69VQ&?
M4ixOFE6QTl4Mkey
NXLU[ZFZT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm=
MU\+OUDPxE1?
NVvIT5NqUUN3ME2wMlQzPSEQvF2=
NF\5TYcyQTl7NkK3Ni=&
NImxOZVIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=
NUHrW5VrhjVizszN
NGHqblVFVVOR
M2m3Z2lEPTB;MD63PUDPxE1?
NFnGZpgyQTl7NkK3Ni=&
M1qz[2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7
NEDWdXB,PSEQvF2=
NGTjR5JFVVOR
MnewTWM2OD1yLkiwOkDPxE1?
Ml3UNVk6QTZ{N{K=
Mn;RS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?
M{\ZS542KM7:TR?=
NFLi[GxFVVOR
NGTXN2FKSzVyPUCuNFA4KM7:TR?=
MYqxPVk6PjJ5Mh?=
NWLneZJmT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm=
M33wSZ42KM7:TR?=
NV;aTHlYUUN3ME2wMlc6KM7:TR?=
NGTYeIgyQTl7NkK3Ni=&
MWLHdo94fGhiaX7obYJqfG:{eTDhd5NigQ&?
Ml\kglUh|ryP
M3GxXGROW09?
MW\JR|UxRTBwMEO3JO69VQ&?
NGrpWWkyQTl7NkK3Ni=&
MWjHdo94fGhiaX7obYJqfG:{eTDhd5NigQ&?
NVjv[JJ1hjVizszN
MXnJR|UxRTBwN{Wg{txO
NX;lTFBkOTl7OU[yO|I&
NU\WZoJZT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm=
MVr+OUDPxE1?
NXXWUmc1TE2VTx?=
M3;jWWlEPTB;MD62PFch|ryP
NVHhOm83OTl7OU[yO|I&
NHzpS|VIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=
NG\wOFB,PSEQvF2=
NHvLRWRFVVOR
Mlq2TWM2OD1yLk[4JO69VQ&?
M{T6PVE6QTl4Mkey
NWXIc|NKT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm=
NHXPPIt,PSEQvF2=
NHvnPINFVVOR
MoLzTWM2OD1yLkm1JO69VQ&?
NHj6cIwyQTl7NkK3Ni=&
M3X2b2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7
NFrnS|R,PSEQvF2=
NEL3fG5KSzVyPUCuOlch|ryP
M4ew[|E6QTl4Mkey
MkDVS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?
NITBNlZ,PSEQvF2=
MYLJR|UxRTFwMkG4JO69VQ&?
NYDYTXRXOTl7OU[yO|I&
NUOyWFhZT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm=
NWS1[5h2hjVizszN
M4XrN2ROW09?
M1ruemlEPTB;MD62N{DPxE1?
NXLydGJkOTl7OU[yO|I&
M2[3Wmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7
M{KwOp42KM7:TR?=
NXj6bVVIUUN3ME2xMlYyQCEQvF2=
MXuxPVk6PjJ5Mh?=
MnrFS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?
Mn;pglUh|ryP
M4XkfmROW09?
NGfzXmZKSzVyPUSuOVIh|ryP
Ml7yNVk6QTZ{N{K=
MnTsS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?
MY\+NVDjiIsQvF2=
NHfaRnhFVVOR
MmXoTWM2OD12Mkigcm0&
NE\tVYczODN6NUe0Oy=&
NHzmVmpIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=
MVL+NVDjiIsQvF2=
NYH1ZWNETE2VTx?=
NFTPdGdKSzVyPUKuPEDPxE1?
Mo\2NlA{QDV5NEe=
MljLS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?
NFvFfWh,OTEkgJtOwG0&
NGLPSGpFVVOR
Mn3VTWM2OD1zIN88US=&
NHzZR5ozODN6NUe0Oy=&
MoTST4lv[XOnIHHzd4F6
MlftglEx6oDMzszN
MmSwSG1UVw&?
MVnpcohq[mm2czDjc45{fGm2dYTpeoUhUUeIMWKgZZV1d3Cqb4PwbI9zgWyjdHnvci=&
M3rlRlIxOzh3N{S3
NGPXZnZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=
MlvNglEx6oDMzszN
M2XneWlEPTB;MT6xNkDDvU1?
MX:yNVI6QDd2NR?=
M1Tnbmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7
MX3+NVDjiIsQvF2=
M{X6bWlEPTB;MD6wO{DDvU1?
Ml23NlEzQTh5NEW=
MYjHdo94fGhiaX7obYJqfG:{eTDhd5NigQ&?
M{\3eJ4yOOLCit88US=&
MVXJR|UxRTRwOU[gxtVO
M3rGW|IyOjl6N{S1
NIfsS4NIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=
MX;+NVDjiIsQvF2=
Mn3iTWM2OD1yLkG5JOK2VQ&?
M3qzTVIyOjl6N{S1
NGG4VoVIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=
M3zqZZ4yOOLCit88US=&
MX\JR|UxRTBwN{igxtVO
MonyNlEzQTh5NEW=
NUeycmpmT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm=
M4HUUZ4yOOLCit88US=&
MUnJR|UxRTBwOEmgxtVO
NFjZemwzOTJ7OEe0OS=&
NInqbZlIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=
NVXTNJdthjFy4pEK{txO
Ml:zTWM2OD1yLkGxJOK2VQ&?
M3To[lIyOjl6N{S1
M2rTO2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7
NH7nO2F,OTEkgJtOwG0&
NFzzT29KSzVyPUCuNVIhyrWP
MYWyNVI6QDd2NR?=
NHPQdmFIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=
M1fiS54yOOLCit88US=&
MoXwTWM2OD1yLk[yJOK2VQ&?
MXSyNVI6QDd2NR?=
M4LiRmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7
NHmweJl,OTEkgJtOwG0&
Mo\PTWM2OD1yLkK3JOK2VQ&?
Mom2NlEzQTh5NEW=
NUnKdnZZT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm=
MUL+NVDjiIsQvF2=
M1jmVWlEPTB;MT60O{DDvU1?
NGf5dpMzOTJ7OEe0OS=&
M3r1SWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7
MXf+NVDjiIsQvF2=
M3jQT2lEPTB;MD6xNkDDvU1?
NI\KR2ozOTJ7OEe0OS=&
NUfvVGp7T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm=
M{OxVp4yOOLCit88US=&
MkLaTWM2OD1yLkO1JOK2VQ&?
MlXENlEzQTh5NEW=
NGCyXI1Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?=
MnjsglEx6oDMzszN
NXu2RnE1UUN3ME2wMlc4KML3TR?=
NWXiclBHOjF{OUi3OFU&
NF7TboFIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=
NXfKc5lyhjFy4pEK{txO
NIe5TWRKSzVyPUCuOVIhyrWP
MXOyNVI6QDd2NR?=
MVjHdo94fGhiaX7obYJqfG:{eTDhd5NigQ&?
NWm4b3JnhjFy4pEK{txO
M2P4eWlEPTB;MD60PUDDvU1?
MlXiNlEzQTh5NEW=
COG-LL-317
MlXvS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?
NYG4SHpLhjFy4pEK{txO
NVHuUXFvUUN3ME2xMlM5KML3TR?=
NV\uSHFqOjF{OUi3OFU&
NFvFSI1Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?=
NXuzOId4hjFy4pEK{txO
Ml7hTWM2OD1yLkO4JOK2VQ&?
MVSyNVI6QDd2NR?=
MWjHdo94fGhiaX7obYJqfG:{eTDhd5NigQ&?
MmfkglEx6oDMzszN
M{TueWlEPTB;MD61N{DDvU1?
MY[yNVI6QDd2NR?=
MULHdo94fGhiaX7obYJqfG:{eTDhd5NigQ&?
NWfEPFdbhjFy4pEK{txO
MVPJR|UxRTFwMUOgxtVO
Mmi1NlEzQTh5NEW=
NEG4ZnZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=
NFG4N3N,OTEkgJtOwG0&
NF\4O3hKSzVyPUGuNkDDvU1?
NFLuXYszOTJ7OEe0OS=&
Karpas-299
MXTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ&?
MUL+NVDjiIsQvF2=
NWTkcJBnUUN3ME2xMlY1KML3TR?=
MknsNlEzQTh5NEW=
NE[zTWhIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=
MXv+NVDjiIsQvF2=
NEjjXFdKSzVyPUGuN|EhyrWP
M1q2flIyOjl6N{S1
MmiySpVv[3Srb36gZZN{[Xl?
NFq2[YxqdmS3Y3XzJIFvKGmwY4LlZZNmKG:oIGPGT{BxcG:|cHjvdplt[XSrb36=
M1HlWFI2QTJ3M{e4
M2DuXGZ2dmO2aX;uJIF{e2G7
M2LodYlv\HWlZYOgZY4hcW6lcnXhd4Uhd2ZiU1\LJJBpd3OyaH;yfYxifGmxbh?=
MlzUNlU6OjV|N{i=
M3[wb2Z2dmO2aX;uJIF{e2G7
MXjpcoR2[2W|IHHuJIlv[3KnYYPlJI9nKFOISzDwbI9{eGixconsZZRqd25?
NWDsdIFUOjV7MkWzO|g&
MXjLbY5ie2ViYYPzZZk&
M1vYSlAvPeLCit88US=&
MkXVSG1UVw&?
NX;GOodwcW6qaXLpeJMhUUeILVnSM2lTKGGldHn2ZZRqd25?
M1K5TVI3QTJ6NUe4
NUDTTnJ2U2mwYYPlJIF{e2G7
MX:wMlXjiIsQvF2=
M2SxfmROW09?
M3TQbYlvcGmkaYTzJGlITi2LUj;JVkBi[3SrdnH0bY9v
M4XNO|I3QTJ6NUe4
NFT2bI1HfW6ldHnvckBie3OjeR?=
NFvm[nAxNjYkgJtOwG0&
Ml\hSG1UVw&?
NH:1NWFk[XW|ZYOgZUBkd26ldYLy[Y51KGSnY4LlZZNmKGmwIIDoc5NxcG:{eXzheIVlKEGNVDDhcoQhTVKN
MYeyOlkzQDV5OB?=
MV7GeY5kfGmxbjDhd5NigQ&?
NVHDXVgzOC534pEK{txO
NHHyV3VFVVOR
NFOwOXVk[XW|ZYOgZUBkd26ldYLy[Y51KGSnY4LlZZNmKGmwIIDoc5NxcG:{eXzheIVlKEGNVDDhcoQhTVKN
NYPoeHpKOjZ7Mki1O|g&
M2nx[Gdzd3e2aDDpcohq[mm2b4L5JIF{e2G7
MoDYglEx6oDMzszN
NHe3d4dFVVOR
M4HWWWlEPTB;MD63OkDPxE1?
NYDMeXI1OjZ7Mki1O|g&
NFLsdHpIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=
NU\jPXVuhjFy4pEK{txO
NULGdlV3TE2VTx?=
NYjO[lB7UUN3ME2xMlA6KM7:TR?=
Ml\VNlY6Ojh3N{i=
MYLBdI9xfG:|aYOgZZN{[Xl?
NYPjdWVZOC534pEK{txO
NVi2RmhnTE2VTx?=
NGfhWIJqdmS3Y3XzJGFxd3C2b4Ppdy=&
MmrKNlY6Ojh3N{i=
NGnpTG5CeG:ydH;zbZMh[XO|YYm=
M4jDc|AvPeLCit88US=&
NWnNT3J3TE2VTx?=
M37JZ4lv\HWlZYOgRZBweHSxc3nz
NYC1OHh[OjZ7Mki1O|g&
NWe5WopuTnWwY4Tpc44h[XO|YYm=
M1P0bVAvPeLCit88US=&
M4PIc2ROW09?
MVzy[YR2[2W|IIfveY5lKGOub4P1doU&
MmTwNlY6Ojh3N{i=
MnnoSpVv[3Srb36gZZN{[Xl?
NV21eXI5OC534pEK{txO
MVPy[YR2[2W|IIfveY5lKGOub4P1doU&
MnraNlY6Ojh3N{i=
BMS-.5mg/kg,口服)作用于携带 IGF-1R-Sal肿瘤的裸鼠，抑制肿瘤和血清中IGF-1R磷酸化。BMS-754807作用于一组选定的上皮(IGF-1R-Sal, GEO, 和Colo205），造血（JJN3）和间质（RD1和Rh41）移植瘤模型，抑制肿瘤生长，肿瘤生长抑制率从53％至115％不等。 BMS-.25 mg/kg) 作用于转基因的IGF-Sal肿瘤小鼠模型，完全抑制肿瘤生长，且抑制pIGF-1R 和 pAKT。BMS-754807与小鼠血浆和人类血浆的蛋白结合率分别为98.5% 和95.9%。BMS- mg/kg)作用于携带KT-5 (Wilms), KT-14 (rhabdoid), Rh28 (rhabdomyosarcoma), 和 OS-1移植瘤的小鼠模型，显著抑制肿瘤。
推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)
激酶实验：
激酶抑制实验:
在体外激酶实验中使用重组人类 IGF-1受体酶测定BMS-754807，在生化实验中使用合成肽KKSRGDYMTMQIG 作为磷酸受体底物测定BMS-754807。在Ubottom 384孔板中使用 30 μL实验缓冲液 (100 mM Hepes pH 7.4, 10 mM MgCl2, 0.015% Brij35 and 4 mM DTT)来进行酶活测定。通过结合ATP，1.5 μM 荧光标记肽底物, 酶和BMS-754807而开始反应，反应持续60分钟。加入EDTA终止反应。通过电泳分离荧光底物和磷酸化产物，然后在Caliper LabChip 3000上分析反应混合物。通过对剂量反应曲线进行非线性回归分析而获得IC50值。
细胞实验：
Cell lines: IGF-1R-Sal, RH41 和 Geo 细胞系
Concentrations: 365 nM
Incubation Time: 72 小时
Method: 细胞按最佳密度培养在RPMI + GLUTAMAX培养基中，培养基中含有有10％ 热灭活的胎牛血清（FBS），10mMHepes，青霉素和链霉素。BMS-754807处理细胞72小时后，通过测定3H-胸甘渗透到DNA中的程度而测评细胞增殖。结果表示为IC50。 (Only for Reference)
动物实验：
Animal Models: 携带IGF-1R-Sal, GEO, Colo205, JJN3, RD1 或 Rh41 肿瘤的裸鼠
Formulation: 聚乙二醇400的混合物[PEG400/水(4:1; vol/vol)]
Dosages: 150 mg/kg
Administration: 口服(Only for Reference)
溶解度 (25°C)
(199.35 mM)
(199.35 mM)
2% DMSO+30% PEG 300+ddH2O
* &1 mg/ml 指产品微溶或不溶
* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。
C23H24FN9O
3 years -20&C powder
2 years -80&C in solvent
摩尔浓度计算器
本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:
质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量
摩尔浓度计算公式
*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。
稀释计算器
用本工具协助配置特定浓度的溶液，使用的计算公式为：
开始浓度 x 开始体积 = 最终浓度 x 最终体积
稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出
在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.
连续稀释计算器方程
分子量计算器
通过输入化合物的化学式来计算其分子量：
总分子量：g/mol
注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2
摩尔浓度计算器
临床试验信息
(data from , updated on )
NCT Number
Recruitment
Conditions
Sponsor/Collaborators
Start Date
Healthy Volunteers
Bristol-Myers Squibb
February 2012
Breast Cancer
Bristol-Myers Squibb|Mayo Clinic
December 2010
Terminated
Colorectal Cancer|Head and Neck Cancer|Neoplasm Metastasis
Bristol-Myers Squibb
October 2009
Phase 1|Phase 2
Bristol-Myers Squibb
September 2009
Breast Cancer
Bristol-Myers Squibb
Phase 1|Phase 2
Advanced Solid Tumors|Metastatic Solid Tumors
Bristol-Myers Squibb
April 2009
在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱，
如果有其他问题，请给我们留言.
*留言内容:
IGF-1R Inhibitors with Unique Features
相关IGF-1R产品
Tags: 购买BMS-754807 | BMS-754807供应商 | 采购BMS-754807 | BMS-754807价格 | BMS-754807生产 | 订购BMS-754807 | BMS-754807代理商
全国免费电话: 400-668-6834&&&&技术支持电话: 400-168-6834
订购及询单: &&&&技术支持:
物流及运输信息: &&&&合作与代理:
Copyright 2013 Selleck中国 . All Rights Reserved.